'Micro-organ' startup Stemonix agrees to merger with public pharma company
August 24, 2020 at 16:16 PM EDT
Stemonix will receive about 78% of Cancer Genetics' 2.31 million outstanding shares, making it the majority owner of the company. At Cancer Genetics's press time share price of around $7, the transaction will be worth $12.6 million to Stemonix.
